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Background: Thiazolidinedione (TZD) treatment has been associated with fractures. The purpose
of this studywas toexamine theassociationbetweenTZDtreatmentandfractures in type2diabetic
patients.
Methods:Usingdata fromTranslatingResearch intoAction forDiabetes, amulticenter prospective
observational study of diabetes care inmanaged care, we conducted amatched case-control study
to assess the odds of TZD exposure in patients with type 2 diabeteswith andwithout fractures.We
identified 786 cases based on fractures detected in health plan administrative data. Up to four
controls without any fracture diagnoses were matched to each case. Controls were matched on
health plan, date of birth within 5 yr, sex, race/ethnicity, and body mass index within 5 kg/m2. We
performed conditional logistic regression for premenopausal and postmenopausal women and
men to assess the odds of exposure to potential risk factors for fracture, including medications,
self-reported limited mobility, and lower-extremity amputations.
Results:Wefound statistically significant increasedoddsof exposure to TZDs, glucocorticoids, loop
diuretics, and self-reported limited mobility for women 50 yr of age and older with fractures.
Exposure to both loop diuretics and TZDs, glucocorticoids, and insulin and limited mobility and
lower-extremity amputation were associated with fractures in men.
Conclusion: Postmenopausalwomen taking TZDs and the subset ofmen taking both loopdiuretics
and TZDs were at increased risk for fractures. In postmenopausal women, risk was associated with
higher TZD dose. No difference between rosiglitazone and pioglitazone was apparent. (J Clin
Endocrinol Metab 95: 4560–4565, 2010)
Thiazolidinediones (TZDs), including rosiglitazone andpioglitazone, have been associated with increased
risk of fractures in postmenopausal women. Both in vivo
and in vitro results have suggested that TZD activation of
peroxisome proliferator-activated receptor-may reduce
bone formation (1). Previous studies were limited to pa-
tients recently diagnosed with type 2 diabetes (2), ex-
cluded patients using other antihyperglycemic medica-
tions (3) and corticosteroids (4), or did not account for
race/ethnicity in the case-control matching criteria (5).
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The purpose of this study was to examine medication
exposures and other factors associated with fractures in
patients with type 2 diabetes. We used data from Trans-
latingResearch intoAction forDiabetes (TRIAD), a large,
prospective, observational study of diabetes care in man-
aged care, to conduct a matched case-control study.
TRIAD studied a geographically, racially, and ethnically
diverse population and provided detailed and robust in-
formation from multiple sources, including patient sur-
veys, medical records, and administrative data.
Patients and Methods
TRIAD has been described in detail previously (6). Six research
centers collaborated with 10 managed care health plans (HPs)
and 68 provider groups that served approximately 180,000 pa-
tients with diabetes. Institutional review boards at each partic-
ipating center approved the study. All participants provided in-
formed consent.
TRIAD enrolled 11,927 patients between July 2000 and
August 2001. All were at least 18 yr old, not pregnant, commu-
nity dwelling, English or Spanish speaking, and continuously
enrolled in themanaged careHP for at least 18months before the
baseline patient survey. Medical record reviews were performed
at baseline, and HP administrative data were collected from 18
months before the baseline survey through 2003. We analyzed
data for patients with type 2 diabetes (we excluded patients who
were diagnosed at30 yr of age and treated only with insulin),
were continuously enrolled, and had a pharmacy benefit as ev-
idenced by multiple medication claims during their enrollment
period. We used HP administrative data to ascertain fractures
and determinemedication exposure.We used patient survey and
medical record reviews to assess duration of diabetes, vision
problems, self-reported limited mobility, lower-extremity am-
putation, andCharlson comorbidity index score.We considered
aperson tobe exposed to amedication if they filled aprescription
during the 90 d before the fracture date for cases or 90 d before
study censor date for controls. The specific medications we ex-
amined and their category assignments are listed in the Supple-
mental Appendix (published on The Endocrine Society’s Jour-
nals Online web site at http://jcem.endojournals.org).
We identified 786 cases based on the earliest diagnosis of a
fracture detected in the administrative data using International
Classification of Diseases, 9th Revision, Clinical Modification
fracture diagnosis codes (with any fourth or fifth digit): 800–
829.The786cases included54women less than50yrof age, 457
women 50 yr of age and older, and 275men. Up to four controls
were matched to each case. Controls had no fracture diagnoses
detected in the administrative data and were matched on HP,
date of birthwithin5 yr, sex, race/ethnicity, andbodymass index
(BMI) within 5 kg/m2. If there were more than four potential
controls for the case, four were randomly selected.
For cases and controls, the study window to assess exposures
started 18 months before the baseline survey. For cases, follow
up ended with the earliest fracture. For controls, the length of
followupwas set equal to that of thematched case by starting 18
months before the baseline survey of the control and extending
the same number of days as the follow up of the matched case
with the last day assigned to be the censor date of the control.
We compared cases and controls using ANOVA (in which the
case-control set was one of the factors) with weighted means and
frequency distributions. We used conditional logistic regression to
provide unadjusted bivariate exposureMantel-Haenszel case-con-
trol odds ratios (ORs). We used conditional logistic regression for
multivariate analyses and for subanalyses by specific TZD (rosigli-
tazone, pioglitazone, and troglitazone) and TZDdose level. Poten-
tial matching variables and risk factors for fracture were identified
from the literature (age, sex, race/ethnicity, and BMI, treatment
with TZDs, bisphosphonates, glucocorticoids, insulin, or loop di-
uretics, reduced vision, self-reported limited mobility, and comor-
bidities).Model variables and interaction termswere selectedbased
on Shtatland’s method using stepwise logistic regression, allowing
all potential predictors to enter andgeneratingSchwarzandAkaike
information criteria to build a parsimoniousmodel (7). The result-
ing model included the following statistically significant risk fac-
tors:exposuretoTZDs,bisphosphonates,glucocorticoids, insulins,
and loopdiuretics, an interaction termfor loopdiuretics andTZDs,
self-reported limited mobility, and lower-extremity amputation.
Patients missing values for variables used in this study were ex-
cluded. Statistical analyses were performed using SAS (version
9.1.3; SAS Institute, Cary, NC).
Results
Troglitazone was approved by the U.S. Food and Drug
Administration in January 1997 and was withdrawn in
March 2000 because of liver toxicity. Troglitazone was
thus available for 2 yr before the beginning of the admin-
istrative data of TRIAD. The first prescription for rosigli-
tazone was filled in June 1999, and the first prescription
for pioglitazone was filled in August 1999. Subsequent
uptake of TZD therapy byTRIADparticipantswas rapid.
The cumulative number of patients with prescriptions for
rosiglitazone was approximately 500, 970, 1250, and
1400 at 1, 2, 3, and 4 yr after the first prescription was
filled. For pioglitazone, it was approximately 500, 800,
1080, and 1300 patients at 1, 2, 3, and 4 yr after the first
prescription was filled.
There were 786 cases and 2657 matched controls. Of
these, 301 cases (38%) experienced lower-limb fractures,
169 (22%) experienced upper-limb fractures, 116 (15%)
experienced pelvis/hip/spine fractures, 72 (9%) experi-
enced multiple fractures, and 128 (16%) did not have the
fracture site specified or the site was designated “other.”
Mean SD duration of follow up was 1.9 1.3 yr, max-
imum follow up was 4.8 yr, and minimum follow up was
less than 1 wk. Cases and controls were matched on HP,
age, sex, race/ethnicity, andBMI.As shown inTable 1, the
cases and controls generally did not differ with respect to
the matching criteria. However, the subgroup of women
with fractures aged 50 yr and over was slightly older than
their matched controls (67.5 vs. 66.2 yr, P  0.046).
Table 2 shows the unadjusted odds of exposures to risk
factors for fractures. Women aged 50 yr and older with
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fractures, when compared with their matched controls
without fractures, were significantly more likely to have
filled prescriptions for TZDs, insulin, glucocorticoids,
loop diuretics, and bisphosphonates, were less likely to
have filled prescriptions for metformin, and were more
likely to have longer duration of diabetes, vision problems
(blurred or double vision), self-reported limited mobility
(some problems walking around or confined to bed), and
higher Charlson comorbidity index scores. The smaller
sample of women under 50 yr of age showed fewer dif-
TABLE 2. Prevalence of exposure and odds of exposure among patients with fractures
Women >50 yr Women <50 yr Men
Number (%)
of cases OR P value
Number (%)
of cases OR P value
Number (%)
of cases OR P value
Sulfonylureas 188 (41%) 0.94 0.57 25 (46%) 0.94 0.84 116 (42%) 0.76 0.053
Metformin 120 (26%) 0.71 0.006* 21 (39%) 0.76 0.42 85 (31%) 0.91 0.55
Sulfonylurea/metformin 9 (2%) 1.18 0.70 0 n/a n/a 5 (2%) 0.97 0.96
Thiazolidinediones 58 (13%) 1.88 0.0004* 5 (9%) 0.56 0.27 38 (14%) 1.79 0.011*
Insulins 128 (28%) 1.36 0.014* 19 (35%) 1.73 0.14 69 (25%) 1.86 0.0003*
Glucocorticoids 67 (15%) 2.08 0.0001* 10 (19%) 2.83 0.034* 33 (12%) 1.90 0.006*
Thyroid drugs 67 (15%) 1.32 0.078 7 (13%) 2.04 0.16 13 (5%) 1.02 0.96
Statins 125 (27%) 0.89 0.38 11 (20%) 1.05 0.91 94 (34%) 1.13 0.42
Loop diuretics 85 (19%) 1.70 0.0003* 8 (15%) 4.76 0.007* 40 (15%) 1.83 0.004*
Proton pump inhibitors 48 (11%) 1.44 0.052 9 (17%) 1.13 0.79 28 (10%) 1.55 0.07
Estrogen with/without
progestin
65 (14%) 0.84 0.27 5 (9%) 0.77 0.64 0 n/a n/a
Selective estrogen
receptor modulators
9 (2%) 1.56 0.31 0 n/a n/a 1 (0%) n/a n/a
Bisphosphonates 16 (4%) 2.16 0.019* 1 (2%) n/a n/a 3 (1%) 2.00 0.36
Calcitonin 4 (1%) 2.78 0.13 0 n/a n/a 0 n/a n/a
Mean diabetes
duration (SD) (yr)
14.9 (12.7) 1.01 0.017* 8.8 (8.0) 1.04 0.08 12.2 (10.2) 1.02 0.016*
Low vision 54 (12%) 1.47 0.029* 8 (16%) 1.45 0.41 20 (8%) 0.98 0.95
Limited mobility 279 (61%) 1.62 0.0001* 32 (59%) 2.26 0.020* 149 (54%) 2.08 0.0001*
Amputation 12 (3%) 1.86 0.098 0 n/a n/a 19 (7%) 2.71 0.002*
Mean Charlson
comorbidity index (SD)
2.65 (1.8) 1.10 0.013* 1.98 (1.0) 1.32 0.10 2.94 (2.0) 1.23 0.0001*
Cases and controls were matched for HP, age, sex, race/ethnicity, and BMI. n/a, Data too sparse. *, P  0.05.
TABLE 1. Characteristics of patients with fractures and matched controls
Women >50 yr Women <50 yr Men
Cases Controls P value Cases Controls P value Cases Controls P value
n 457 1534 54 177 275 946
Weighted mean age
(SD) (yr)
67.5 (9.7) 66.2 (9.2) 0.046 44.8 (4.0) 44.9 (4.6) 0.88 62.7 (12.3) 62.4 (11.7) 0.75
Weighted mean BMI
(SD) (kg/m2)
31.3 (6.5) 31.3 (5.9) 0.93 36.0 (7.9) 35.4 (7.3) 0.69 30.1 (5.8) 29.9 (4.9) 0.59
Race/ethnicity 1.00 1.00 1.00
Hispanic (%) 16.8 16.8 18.5 18.5 10.9 10.9
Black (%) 18.8 18.8 16.7 16.7 11.6 11.6
White (%) 46.2 46.2 38.9 38.9 56.4 56.4
Asian/Pacific
Islander (%)
10.9 10.9 14.8 14.8 11.3 11.3
Other (%) 7.2 7.2 11.1 11.1 9.8 9.8
HP 1.00 1.00 1.00
A (%) 8.8 8.8 1.8 1.8 8.0 8.0
B (%) 7.4 7.4 16.7 16.7 9.1 9.1
C (%) 15.3 15.3 29.6 29.6 9.5 9.5
D (%) 16.6 16.6 16.7 16.7 19.6 19.6
E (%) 21.2 21.2 16.7 16.7 22.9 22.9
F (%) 2.4 2.4 1.8 1.8 6.5 6.5
G (%) 5.7 5.7 0 0 5.4 5.4
H (%) 2.4 2.4 3.7 3.7 5.1 5.1
I (%) 20.1 20.1 13.0 13.0 13.8 13.8
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ferences between cases and controls, with cases signifi-
cantlymore likely tohave filledprescriptions for glucocor-
ticoids and loop diuretics and more likely to have limited
mobility. For men, cases were significantly more likely to
have filled prescriptions for TZDs, insulin, glucocorti-
coids, and loop diuretics and to have longer duration of
diabetes, limited mobility, lower-extremity amputations,
and higher Charlson comorbidity index scores.
Table 3 shows the adjustedORs of exposure to various
risk factors in cases compared with controls. Among
women aged 50 yr and older, cases with fractures were
significantlymore likely (P0.05) to be exposed toTZDs
[OR of 1.71, 95% confidence interval (CI) of 1.13–2.58],
glucocorticoids (OR of 1.90, 95% CI of 1.36–2.65), and
loop diuretics (OR of 1.49, 95% CI of 1.08–2.06) and to
have limitedmobility (ORof 1.51, 95%CI of 1.20–1.90).
We did not find TZDs to be significantly associated with
fractures inwomen less than50yr of age, although the risk
factors associated with fractures were generally similar to
those for women aged 50 yr and older. In men, we found
fractures tobe significantly associatedwith concurrent use
of loop diuretics and TZDs (ORof 3.46, 95%CI of 1.06–
11.28), exposure to glucocorticoids (OR of 1.79, 95%CI
of 1.11–2.87), and insulin (OR of 1.59, 95% CI of 1.11–
2.29), as well as limited mobility (OR of 1.96, 95% CI of
1.45–2.65) and lower-extremity amputation (ORof 2.29,
95% CI of 1.21–4.32).
We examined duration of TZD exposure before frac-
ture for those filling prescriptions for TZDs. We were un-
able to determine duration of troglitazone exposure be-
cause troglitazone treatment may have been initiated
before the beginning of our study. For the 84women aged
50 yr and older, average duration of TZDexposure before
fracturewas 364d (interquartile range of 100–582d). For
the eightwomenunderage50yr, averagedurationofTZD
exposure before fracture was 521 d (interquartile range of
315–750 d). For the 54 men, average duration of TZD
exposure before fracture was 449 d (interquartile range of
180–597 d).
We also assessed the impact of TZD dose on the odds
of fracture. We categorized the TZD dose level as “low”
or “high.” For pioglitazone, 15mgwas assigned low dose
and 30–45 mg was assigned high dose. For rosiglitazone,
2–4mgwas assigned lowdose and8mgwas assignedhigh
dose. For troglitazone, 200mgwas assigned low dose and
300–400mgwas assigned high dose. Themodel included
exposure to bisphosphonates, glucocorticoids, insulin,
and loopdiuretics and limitedmobility and lower-extrem-
ity amputation. High TZD doses were associated with
significantly greater odds of fracture for women age 50 yr
and older (OR of 1.42, 95% CI of 1.12–1.79) but not for
men or women under age 50 yr.
To assess the risk of fractures associated with rosigli-
tazone, pioglitazone, and troglitazone, we performed a
subanalysis with the individual TZDs as separate vari-
ables inmodels thatwere otherwise the same as those used
above. For women 50 yr of age and older, the odds of
exposure was similar for rosiglitazone (OR of 1.64, 95%
CI of 0.96–2.80) and pioglitazone (OR of 1.56, 95% CI
of 0.89–2.74). For troglitazone, we found the odds of
exposure to be 4.23 (95% CI of 1.30–13.75).
Discussion
In this large, prospective, observational study of diabetes
care in managed care, we used a matched case-control
design and found that women 50 yr of age and older with
fracturesweremore likely to be exposed toTZDs.Women
aged 50 yr and older developed fractures after shorter
duration ofTZDexposure thanwomenunder age 50 yr or
men.HigherdoseofTZDwasassociatedwithgreater risk.
Both rosiglitazone and pioglitazone appeared to be asso-
ciated with increased risk. Limited mobility was associ-
ated with fractures for both women 50 yr of age and older
and men. Higher odds of fractures were found for men
using both TZDs and loop diuretics and for men with
lower-extremity amputations. Duration of diabetes and
TABLE 3. Multivariate ORs
Women >50 yr
OR (95% CI)
Women <50 yr
OR (95% CI)
Men
OR (95% CI)
Thiazolidinediones 1.71 (1.13–2.58)* 0.38 (0.10–1.39) 1.37 (0.83–2.28)
Bisphosphonates 1.85 (0.94–3.63) 1.69 (0.37–7.85)
Glucocorticoids 1.90 (1.36–2.65)* 2.26 (0.78–6.54) 1.79 (1.11–2.87)*
Insulins 1.12 (0.86–1.45) 1.48 (0.66–3.30) 1.59 (1.11–2.29)*
Loop diuretics 1.49 (1.08–2.06)* 3.31 (0.81–13.44) 1.09 (0.66–1.79)
Interaction loop diuretics
and thiazolidinediones
0.99 (0.44–2.24) 2.26 (0.10–48.94) 3.46 (1.06–11.28)*
Limited mobility 1.51 (1.20–1.90)* 2.01 (0.99–4.07) 1.96 (1.45–2.65)*
Amputation 1.30 (0.61–2.79) 2.29 (1.21–4.32)*
Cases and controls were matched for HP, age, sex, race/ethnicity, and BMI. Variables excluded from the model for this population because of
insufficient observations. *, P  0.05.
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Charlson comorbidity index scorewere not independently
associated with fractures.
A Diabetes Outcomes Progression Trial (ADOPT)
found higher fracture rates in women randomized to ros-
iglitazone than in women randomized to metformin or
sulfonylureas (2). The association betweenTZDexposure
and fractures in women was confirmed by post hoc anal-
yses of earlier clinical trials (8, 9). Subsequent analyses of
stored serum samples from ADOPT participants sug-
gested that increased bone resorption may have contrib-
uted to increased risk of fractures in women taking TZDs
(10). ADOPT was limited to drug-naive patients diag-
nosedwith type 2 diabetes within the previous 3 yr. In our
study, the cases and controls averaged over 12 yr since
diagnosis. In ADOPT and in our study, the majority of
fractures were not typical osteoporotic fractures. In
ADOPT, lower-limb fractures accounted for 53%of frac-
tures in women and 28% of fractures in men treated with
rosiglitazone. In our study 62% of fractures in women
taking TZDs and 43% of fractures in men taking TZDs
were lower-limb fractures. In ADOPT, upper-limb frac-
tures accounted for 34% of fractures in women and 31%
of fractures inmen treatedwith rosiglitazone. Inour study,
20% of fractures in women taking TZDs and 16% of
fractures in men taking TZDs were upper-limb fractures.
In our study, 44% of all fractures in women and 39% of
all fractures in men involved the lower limb, and 25% of
all fractures in women and 21% of all fractures in men
involved the upper limb.
Additional studies have confirmed an increased risk of
fractures in patients taking TZDs. Eight subjects (six
women, two men) randomized to pioglitazone in the
PERISCOPE study (for Pioglitazone Effect on Regression
of Intravascular Sonographic Coronary Obstruction Pro-
spective Evaluation) experienced fractures. Nonewere re-
ported in the control group (11). A recent cross-sectional
study that excluded patients treated with corticosteroids
foundhigher rates of fractures for those takingTZDscom-
pared with those not taking TZDs (4). A retrospective
cohort study examining time to fracture foundTZDuse to
be associated with increased fracture risk overall and in
women over 65 yr of age (12). An observational study of
older, low-income patients in a single state found patients
prescribedTZDsas theironlyoral antidiabeticmedication
were more likely to develop fractures than patients pre-
scribedadifferent single oral antidiabeticmedication (13).
Anotherprospective cohort study foundpioglitazone tobe
associated with more extremity fractures in men and
women but did not find the same effect for rosiglitazone
(3). The latter study used a new-user design and excluded
patients with sulfonylurea, TZD, or insulin treatment in
the previous 2 yr.Our studydidnot excludepatients based
on current medication regimen so the subjects were per-
haps more representative of the general population of pa-
tients with type 2 diabetes. A recent study found an asso-
ciation between fractures andTZDuse and suggested that
fracture was associated with higher TZD dose (5). We
confirmed theTZDdose-response effect.A self-controlled
case-series study using the United KingdomGeneral Prac-
tice Research Database found increased fracture risk dur-
ing periods of TZD exposure (14). Subjects were selected
with evidence of fracture and TZD prescriptions. The
study did not include subjects using TZDs who did not
experience fractures. The unexposed period was defined
as before the initial TZD prescription. Because the unex-
posed period always preceded the exposed period, the au-
thors adjusted for age, although the approach could be
complicated by possible development of comorbidities
over time. The study was not able to distinguish type 1
fromtype2diabetes. InTRIAD,weexcludedpatientswith
probable type 1 diabetes.
Our finding of increased risk of fracture in men asso-
ciatedwith concurrent use of loopdiuretics andTZDswas
interesting because, in men, loop diuretics or TZDs alone
did not confer significant risk. In recent studies, loop di-
uretics havebeenassociatedwith fractures inolderwomen
(15, 16) and with bone loss in older men (17, 18). If this
result is confirmed by others, additional research on po-
tential mechanisms is warranted.
Troglitazone was the only TZD available before the
beginning of our study. Our finding of a significant asso-
ciation between fractures and prescriptions for troglita-
zone inwomenaged50 yr andover suggests that increased
risk may be associated with longer duration of exposure.
Reexamination of historical data on troglitazone-treated
patients may help explain the higher fracture risk associ-
ated with troglitazone exposure.
Our analyses used multiple sources of data, including
surveys, medical records, and administrative data. Our
analyses did have several limitations. We relied on phar-
macy prescriptions and, if a patient’s HP coverage in-
cluded a limit on pharmacy benefits, patients may have
filled prescriptions that we did not detect. We expect this
error to be small because we verified that patients were
filling prescriptions while enrolled in the HP, and two
largeHPs submitted pharmacy utilization, not just claims,
capturingprescriptions thatwerenot covered. In addition,
most HPs included denied claims, further capturing pre-
scriptions that were not covered. Our study included a
small number of women under 50 yr of age, and, although
the results are shown, we are unable to draw firm conclu-
sions regarding fracture risk associated with TZDs in this
small population.Wedidnot inspect x-raydata to confirm
fracture diagnoses. We relied on administrative data
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sources. Matched case-control studies control for differ-
ences in the distributions of the matching variables be-
tween cases and controls. In our study, this removed the
potential impact of differences in HP, age, sex, race/eth-
nicity, and BMI on fracture risk. However, matched case-
control studies do not adjust for variables that are not
matched, and this could have resulted in residual con-
founding (19).
In conclusion, we confirmed the increased risk of frac-
tures for older women treated with TZDs and identified
increased risk of fracture in men who are concurrently
taking loop diuretics and TZDs. Risk was associated with
higher TZD dose, but no difference between rosiglitazone
and pioglitazonewas apparent, suggesting a class effect of
TZDs on fracture risk. Future studies, particularly long-
term, prospective randomized clinical trials, will be
needed to conclusively demonstrate small to moderate
harm (20).
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